<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240709062370N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-07-15</date_registration>
      <primary_sponsor>The University of Isfahan</primary_sponsor>
      <public_title>Optimizing Rehabilitation in People with Multiple Sclerosis</public_title>
      <acronym></acronym>
      <scientific_title>Optimizing Rehabilitation in People with Multiple Sclerosis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-08-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/77831</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: A simple randomization method. For this purpose, the participants were listed alphabetically and each participant was assigned numbers one and two from this list. The unit of randomization was individual, and randomization was produced and applied using Excel software and the combination of two commands, SORTBY and ARRAYRAND. By applying this method, each participant will be randomly replaced in the control or optimal group, and the role of all related/unrelated variables in the selection of participants in the two groups will be randomly neutralized, Blinding description: The participants of both groups of this study will be told in general that they are going to participate in a course of personalized stepping exercises for MS patients. Permission to use this trial was obtained from the ethics committee.
It should be noted that the type of exercises of both groups will be exactly the same and the only difference between the groups is the feedback they receive while performing the movement exercises. All items measured in the pre-test and post-test, the instructions given/not given to perform the tests and movement exercises will be exactly the same for all participants. The participants of both groups will be unaware of the exact purpose of doing the exercises that are included in the specific research hypotheses.
However, all participants (MS patients) will be blinded in the study.

At the time of allocating the participants to the control and optimal groups, according to the method used for randomization, both the participants and the researcher will be unaware of the allocation of the participants in the study groups and has no role in the allocation. However, due to the nature of the trials that will be applied over 8 weeks, there will be differences in the feedback provided to the groups. To avoid the bias of the evaluators/trainers, one person is used for this purpose for both groups. Therefore, during the experiments, the main researcher (evaluator/trainer) will necessarily know which group each participant belongs to. For this reason, the one-sided blind study option was chosen and it cannot be considered completely double-blind.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Multiple Sclerosis (MS).</hc_freetext>
      <i_freetext>Intervention 1: The optimal group (intervention): this group will participate in exactly the same pre-tests and post-tests as the control group. The equipment used, the duration of training sessions, and the length of the trial period of this group will be exactly the same as the control group and will be 8 weeks. The only difference will be in the content of the feedback provided during the practice sessions. Intervention 2: Control group: This group will participate in exactly the same pre-tests and post-tests as the optimal (experimental) group. The equipment used, the duration of training sessions, and the length of the trial period of this group will be exactly the same as the optimal group and 8 weeks. The only difference will be in the content of the feedback provided during the practice sessions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is This will be done if there is a request for data.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamid Salehi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>The University of Isfahan, Azadi Square, Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673444</zip>
        <telephone>+98 31 3793 2577</telephone>
        <email>Dr.Salehi@gmail.com</email>
        <affiliation>The University of Isfahan</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamid Salehi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>The University of Isfahan, Azadi square, Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673444</zip>
        <telephone>0098</telephone>
        <email>Salehi@spr.ui.ac.ir</email>
        <affiliation>The University of Isfahan</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>clinical diagnosis of MS
years of age 30-50
patients with a range of disabilities, with scores on the Expanded Disability Status Scale (EDSS) from 2.00 to 4.00
ability to walk without aid (e.g., cane),</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>cognitive impairments
other neurologic disorders
severe contracture in the lower limbs</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G35</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Multiple sclerosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The optimal group (intervention): this group will participate in exactly the same pre-tests and post-tests as the control group. The equipment used, the duration of training sessions, and the length of the trial period of this group will be exactly the same as the control group and will be 8 weeks. The only difference will be in the content of the feedback provided during the practice sessions.</i_keyword>
      <i_keyword>Control group: This group will participate in exactly the same pre-tests and post-tests as the optimal (experimental) group. The equipment used, the duration of training sessions, and the length of the trial period of this group will be exactly the same as the optimal group and 8 weeks. The only difference will be in the content of the feedback provided during the practice sessions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Static and dynamic balance. Timepoint: Pre test, mid test, post test. Method of measurement: Timed Up and Go test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Static and dynamic balance. Timepoint: Pre test, Post test. Method of measurement: Timed Up and Go test (TUG).</sec_outcome>
      <sec_outcome>Depression symptoms. Timepoint: Pre test, Post test. Method of measurement: Beck Depression Inventory.</sec_outcome>
      <sec_outcome>Walking speed. Timepoint: Pre test, Post test. Method of measurement: 25 foot walking.</sec_outcome>
      <sec_outcome>Fatigue. Timepoint: Post test. Method of measurement: The Fatigue Scale for Motor and Cognitive Functions, Multiple Sclerosis.</sec_outcome>
      <sec_outcome>Quality of life. Timepoint: Post test. Method of measurement: Multiple Sclerosis Impact Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The University of Isfahan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-12-23</approval_date>
        <contact_name>Research Ethics Committees of University of Isfahan</contact_name>
        <contact_address>the University of Isfahan, Azadi square, Isfahan Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
